The firm plans to study the PI3K/AKT/mTOR inhibitor paxalisib in combination with Merck's Keytruda in microsatellite stable and proficient mismatch repair colorectal cancer.

New products for the week of Aug. 31, 2026: BillionToOne, Mirxes, OGT, and Eclipse Bioinnovations.

Transcriptomic and metabolomic analyses of blood samples collected over eight years identified population-level patterns and variable individual trajectories.

The Fitrapid test is a noninvasive at-home kit designed to detect fecal occult blood, an early warning sign of lower gastrointestinal tract diseases.

Huanjia Zhang covers sequencing and omics technologies. He earned a bachelor’s degree in biology at Gettysburg College and a master’s degree in journalism from New York University’s Science, Health ...

The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share,  noting their strong positions in non-oncology markets and recent moves into cancer testing.

AstraZeneca will also share data with regulators from a Phase III study of Tagrisso and Orapthys in lung cancer.

The firm expects to file a biologics license application in the US for OCU410 in 2028 based on data from this Phase III program.

The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.